An announcement from Bon Natural Life ( (BON) ) is now available.
On February 19, 2025, Bon Natural Life Limited’s subsidiary, Xi’an App-Chem Bio (Tech) Co., Ltd, entered into a significant 24-month supply agreement with Shanghai Yunsheng International Trading Co., Ltd. This $12 million deal involves the supply of apple polyphenol health products, including beverages and tablet candy, leveraging BON’s patented extraction technology. The agreement underscores BON’s strategic positioning in the high-growth niche of apple polyphenol-infused health solutions, aiming to capitalize on the increasing consumer demand for nutraceutical products. This partnership is expected to enhance BON’s market presence and revenue streams, as it combines antioxidant-rich apple polyphenols with plant-based proteins to support weight management and metabolic health.
Spark’s Take on BON Stock
According to Spark, TipRanks’ AI Analyst, BON is a Neutral.
The overall score for Bon Natural Life is driven by significant challenges in financial performance, including declining revenue and negative cash flow, which weigh heavily on the stock. The technical analysis indicates a persistent downtrend, further impacting the score. While the stock’s low P/E ratio suggests potential undervaluation, it may be due to market skepticism about the company’s prospects. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on BON stock, click here.
More about Bon Natural Life
Bon Natural Life Limited (BON) is a Cayman Islands company operating in the natural, health, and personal care industries. It is recognized as a leading bio-ingredient solution provider, focusing on the development of health products that incorporate natural extracts and functional ingredients.
YTD Price Performance: -96.45%
Average Trading Volume: 15,434,609
Technical Sentiment Signal: Strong Buy
Current Market Cap: $240.2K
For an in-depth examination of BON stock, go to TipRanks’ Stock Analysis page.